Alpidem

Alpidem
Alpidem.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Alpidem is a pharmacological agent that belongs to the class of anxiolytic drugs. It was developed as a non-benzodiazepine anxiolytic, primarily used for the treatment of anxiety disorders.

Pharmacology

Alpidem acts as a selective agonist at the GABA_A receptor, which is a major inhibitory neurotransmitter receptor in the central nervous system. Unlike traditional benzodiazepines, alpidem has a unique chemical structure that allows it to bind selectively to certain subtypes of the GABA_A receptor, potentially offering anxiolytic effects with a reduced risk of sedation and dependence.

Clinical Use

Alpidem was initially marketed for the treatment of anxiety disorders, offering an alternative to benzodiazepines. Its selective action was thought to provide anxiolytic benefits without the common side effects associated with benzodiazepines, such as drowsiness and muscle relaxation.

Side Effects

Common side effects of alpidem include dizziness, headache, and nausea. In some cases, patients may experience gastrointestinal disturbances or allergic reactions. Due to its action on the central nervous system, there is also a potential for psychological dependence.

Regulatory Status

Alpidem was withdrawn from the market in several countries due to concerns about hepatotoxicity and other adverse effects. Its use is currently restricted or banned in many regions, and it is not widely available for clinical use.

Chemical Properties

Alpidem is chemically distinct from benzodiazepines, featuring a unique structure that contributes to its selective receptor binding. The chemical formula of alpidem is C21H23ClN4O, and it is typically synthesized in a laboratory setting.

Related pages

• Anxiolytic
• GABA_A receptor
• Benzodiazepine
• Hepatotoxicity

• 
  Alpidem

• 
  Alpidem